DE69902523T2 - Verwendung von erythropoietin zur behandlung von multiple myelom - Google Patents
Verwendung von erythropoietin zur behandlung von multiple myelomInfo
- Publication number
- DE69902523T2 DE69902523T2 DE69902523T DE69902523T DE69902523T2 DE 69902523 T2 DE69902523 T2 DE 69902523T2 DE 69902523 T DE69902523 T DE 69902523T DE 69902523 T DE69902523 T DE 69902523T DE 69902523 T2 DE69902523 T2 DE 69902523T2
- Authority
- DE
- Germany
- Prior art keywords
- erythropoietin
- multiple myeloma
- treating multiple
- cancer
- inhibition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL12401598A IL124015A0 (en) | 1998-04-08 | 1998-04-08 | Pharmaceutical compositions comprising a protein |
PCT/IL1999/000186 WO1999052543A2 (en) | 1998-04-08 | 1999-03-30 | Pharmaceutical compositions comprising erythropoietin for treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69902523D1 DE69902523D1 (de) | 2002-09-19 |
DE69902523T2 true DE69902523T2 (de) | 2003-04-24 |
Family
ID=11071408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69902523T Expired - Lifetime DE69902523T2 (de) | 1998-04-08 | 1999-03-30 | Verwendung von erythropoietin zur behandlung von multiple myelom |
Country Status (11)
Country | Link |
---|---|
US (2) | US6579525B1 (de) |
EP (1) | EP1067955B1 (de) |
JP (1) | JP4456271B2 (de) |
AT (1) | ATE222119T1 (de) |
AU (1) | AU3052799A (de) |
CA (1) | CA2366674C (de) |
DE (1) | DE69902523T2 (de) |
ES (1) | ES2185323T3 (de) |
HK (1) | HK1033910A1 (de) |
IL (2) | IL124015A0 (de) |
WO (1) | WO1999052543A2 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001082952A2 (en) * | 2000-05-02 | 2001-11-08 | Action Pharma Aps | USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS |
DE10219545A1 (de) * | 2002-04-26 | 2003-11-06 | Lang Florian | Regulation der Apoptose |
EP3053579A1 (de) | 2004-03-15 | 2016-08-10 | Sunesis Pharmaceuticals, Inc. | Verwendung von sns-595 zur behandlung von eierstockkrebs |
US7588745B2 (en) * | 2004-04-13 | 2009-09-15 | Si Options, Llc | Silicon-containing products |
US20080233149A1 (en) * | 2004-07-12 | 2008-09-25 | Yeda Research And Development Co. Ltd. | Use of Erythropoietin for Enhancing Immune Responses and for Treatment of Lymphoproliferative Disorders |
US8580814B2 (en) * | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
WO2007146335A2 (en) | 2006-06-12 | 2007-12-21 | Sunesis Pharmaceuticals, Inc. | Compounds and compositions for treatment of cancer |
SG188161A1 (en) | 2008-01-22 | 2013-03-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
EP3103880A1 (de) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Modifizierte leptinpolypeptide und deren verwendungen |
UA118536C2 (uk) | 2008-07-23 | 2019-02-11 | Амбркс, Інк. | Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування |
EP3216800A1 (de) | 2008-09-26 | 2017-09-13 | Ambrx, Inc. | Modifizierte tierische erythropoietin-polypeptide und deren verwendungen |
EA200900517A1 (ru) * | 2009-04-01 | 2010-08-30 | Общество С Ограниченной Ответственностью "Лэнс-Фарм" | Применение эритропоэтина для лечения миелобластного лейкоза |
TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
JP6479789B2 (ja) * | 2013-07-17 | 2019-03-13 | アライム ファーマシューティカルズ,インコーポレーテッド | 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体 |
WO2015189813A1 (en) | 2014-06-12 | 2015-12-17 | Andremacon S.R.L. | Use of negative functional modulators of erythropoietin for therapy |
PL230756B1 (pl) * | 2015-09-11 | 2018-12-31 | Univ Medyczny W Bialymstoku | Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu |
CN106075447B (zh) * | 2016-06-24 | 2018-07-10 | 中国人民解放军第二军医大学 | 一种epo受体及其在伴红细胞增多症的肝细胞癌中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100263845B1 (ko) | 1989-10-13 | 2000-08-16 | 스튜어트 엘.왓트 | 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물 |
US6012450A (en) * | 1993-01-29 | 2000-01-11 | Aradigm Corporation | Intrapulmonary delivery of hematopoietic drug |
US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
-
1998
- 1998-04-08 IL IL12401598A patent/IL124015A0/xx unknown
-
1999
- 1999-03-30 EP EP99912039A patent/EP1067955B1/de not_active Expired - Lifetime
- 1999-03-30 DE DE69902523T patent/DE69902523T2/de not_active Expired - Lifetime
- 1999-03-30 CA CA2366674A patent/CA2366674C/en not_active Expired - Fee Related
- 1999-03-30 US US09/647,761 patent/US6579525B1/en not_active Expired - Lifetime
- 1999-03-30 AT AT99912039T patent/ATE222119T1/de active
- 1999-03-30 JP JP2000543153A patent/JP4456271B2/ja not_active Expired - Fee Related
- 1999-03-30 AU AU30527/99A patent/AU3052799A/en not_active Abandoned
- 1999-03-30 ES ES99912039T patent/ES2185323T3/es not_active Expired - Lifetime
- 1999-03-30 WO PCT/IL1999/000186 patent/WO1999052543A2/en active IP Right Grant
-
2000
- 2000-09-26 IL IL138705A patent/IL138705A/en not_active IP Right Cessation
-
2001
- 2001-07-05 HK HK01104635A patent/HK1033910A1/xx not_active IP Right Cessation
-
2003
- 2003-03-05 US US10/378,970 patent/US20030216316A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2366674C (en) | 2010-12-21 |
EP1067955B1 (de) | 2002-08-14 |
AU3052799A (en) | 1999-11-01 |
US20030216316A1 (en) | 2003-11-20 |
ES2185323T3 (es) | 2003-04-16 |
ATE222119T1 (de) | 2002-08-15 |
IL138705A (en) | 2007-02-11 |
EP1067955A2 (de) | 2001-01-17 |
WO1999052543A2 (en) | 1999-10-21 |
DE69902523D1 (de) | 2002-09-19 |
JP2002511419A (ja) | 2002-04-16 |
JP4456271B2 (ja) | 2010-04-28 |
WO1999052543A3 (en) | 1999-12-16 |
IL124015A0 (en) | 1999-01-26 |
US6579525B1 (en) | 2003-06-17 |
HK1033910A1 (en) | 2001-10-05 |
CA2366674A1 (en) | 1999-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69902523D1 (de) | Verwendung von erythropoietin zur behandlung von multiple myelom | |
DE59903921D1 (de) | Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen | |
EA199800391A1 (ru) | Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору | |
ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
DE60114580D1 (de) | Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen | |
DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
DE60139689D1 (de) | Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs. | |
ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
ATE230607T1 (de) | Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust | |
ATE415962T1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
DE69911210D1 (de) | Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs | |
WO2003103581A3 (en) | COMPOSITIONS AND METHODS FOR LIVER GROWTH AND PROTECTION | |
ATE311853T1 (de) | Verwendung von krillenzymen zur behandlung von zahnbelag | |
ATE238792T1 (de) | Verwendung von makroliden zur behandlung von glaukom | |
ATE271873T1 (de) | Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz | |
DE69918972D1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
DE60123138D1 (de) | Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs | |
DE59900286D1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
ATE261724T1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen | |
DE60106604D1 (de) | Verwendung von aloe-emodin zur behandlung von neuroektodermalen tumoren | |
ATE369143T1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
ATE365718T1 (de) | Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten | |
DE59911556D1 (de) | Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor | |
DE59904564D1 (de) | Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien | |
ATE291434T1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |